CTOs on the Move

Syantra

www.syantra.com

 
With a cancer diagnosis, early detection means better outcomes. It means hope. But when it comes to breast cancer, more than half of women have a reduced opportunity for an early, life-saving diagnosis. That`s why we`re developing Syantra DX: a blood test to detect breast cancer. It`s a revolutionary, rapid, economical approach to breast cancer screening that`s accurate regardless of the test recipient`s family history, age or tissue density.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.syantra.com
  • 105 - 32 Royal Vista Drive NW
    Calgary, AB CAN T3R 0H9
  • Phone: 877.331.0516

Executives

Name Title Contact Details

Similar Companies

Glycomine

There are approximately 7,000 rare disorders worldwide. Each day more are being discovered. 95% of rare diseases have not one single FDA approved treatment. Glycomine develops therapeutics for diseases which have no treatment options.

Yield10 Bioscience

Yield10 Bioscience is an agricultural bioscience company focusing on the development of disruptive technologies to produce step-change improvements in crop yield for food and feed crops to enhance global food security. Experts forecast that food production must be increased by over 70% in the next 35 years to feed the growing global population, which is expected to increase from 7 billion to more than 9.6 billion by 2050. Yield10 is focused on new agricultural biotechnology approaches to improve fundamental elements of plant metabolism through enhanced photosynthetic efficiency and directed carbon utilization. Yield10 is working to develop, validate and commercialize new traits and identify gene editing targets in several key crops including canola, soybean and corn. Yield10 was launched by Metabolix, Inc. in 2015 and is traded on Nasdaq (YTEN). Yield10 is headquartered in Woburn, MA and has an additional agricultural science facility with greenhouses in Saskatoon, Saskatchewan, Canada.

Linkage Inc

Linkage Inc is a Burlington, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Plexium

Plexium is the premier, next-generation Targeted Protein Degradation (TPD) company seeking to discover a wide range of monovalent target protein degraders that address the limitations of heterobifunctional degraders and cereblon IMiDs. The company is powered by its proprietary drug discovery platform designed to identify novel small molecules that induce selective degradation of drug target proteins through E3 ligase mediated proteasomal degradation. From molecular glues to monovalent degraders, Plexium is advancing a pipeline of novel targeted protein degraders for the treatment of cancer, neurodegeneration, and other diseases. Due to its expertise in TPD, Plexium has entered into strategic collaborations with Amgen and AbbVie to discover and develop a wide range of new therapies from cancer to neurological diseases. Supported by high quality investors, Plexium is well positioned to transform medicine.

Terumo Heart

Terumo Heart, Inc. is a Ann Arbor, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.